Lonza Expands Cell and Gene Therapy Portfolio

Lonza Group AG has broadened its suite of cell and gene therapy manufacturing solutions with the launch of two new products: TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium. The additions are aimed at enhancing the scalability and consistency of advanced therapy production under Good Manufacturing Practice (GMP) conditions.

The TheraPEAK AmpliCell Cytokines are designed to support immune cell expansion, activation, and differentiation. Manufactured using a mammalian expression system, the cytokines are engineered for high biological activity and structural fidelity, offering advantages over bacterial systems in terms of folding, glycosylation, and batch consistency. The company said the product is intended to improve predictability in both research and clinical manufacturing environments.

TheraPEAK 293-GT Medium, meanwhile, is a chemically defined, animal-origin-free formulation optimized for adeno-associated virus (AAV) production in suspension HEK293 cells. Lonza said the medium is compatible with existing transfection reagents and AAV enhancers, and supports high full-to-empty capsid ratios—an important metric in gene therapy vector production.

Both products are part of Lonza’s TheraPEAK portfolio, which the company says has been used in FDA-approved therapies and over 130 clinical trials globally.

“The introduction of AmpliCell Cytokines and the 293-GT Medium to our TheraPEAK Range greatly enhances our offering for cell and gene therapy customers, providing them with reliable solutions to support their drug development efforts,” said Mike Goetter, Head of Bioscience, Specialized Modalities at Lonza.